Novan to Report Full Year 2022 Financial Results on March 30, 2023
23 mars 2023 09h00 HE
|
Novan, Inc.
DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2022 financial results on Thursday,...
Tekumo Adding Three Development Team Leads for Core Product Offering
20 mars 2023 10h07 HE
|
Balincan USA, Inc.
New York , March 20, 2023 (GLOBE NEWSWIRE) -- Balincan USA Inc. (OTC: BCNN, TKMO pending FINRA approval, "Balincan '' or the "Company") today announced the hiring of three new engineers to lead...
Novan Announces Closing of $6.0 Million Registered Direct Offering
16 mars 2023 16h15 HE
|
Novan, Inc.
DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the issuance and sale in the Company’s previously announced...
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference
14 mars 2023 08h30 HE
|
Novan, Inc.
DURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan,...
Novan Announces $6.0 Million Registered Direct Offering
14 mars 2023 08h00 HE
|
Novan, Inc.
DURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has entered into definitive agreements for the issuance and sale in a...
Novan Moves Forward with Unified Corporate Branding
08 mars 2023 09h00 HE
|
Novan, Inc.
– Novan is a fully integrated pharmaceutical company with proven capabilities across drug development through to commercialization – – EPI Health adopts Novan corporate branding, creating unified...
FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024
07 mars 2023 08h00 HE
|
Novan, Inc.
– FDA completes filing review of application with no filing issues identified – – New Chemical Entity (“NCE”) has potential to be the first FDA-approved prescription product for molluscum in the...
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
18 janv. 2023 08h05 HE
|
Novan, Inc.
DURHAM, N.C., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will...
Stonewall Kitchen Announces New January 2023 Product Launch
09 janv. 2023 01h00 HE
|
Stonewall Kitchen
YORK, Maine, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Stonewall Kitchen and its family of brands are pleased to announce their new January product launch, which introduces over 50 new items into the...
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
06 janv. 2023 08h00 HE
|
Novan, Inc.
– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines – – Molluscum contagiosum is a viral skin infection that...